New research has shown that neuroendocrine tumors are more common than previously thought. Progress in our understanding of the molecular pathogenesis of these not-so-rare cancers has resulted in renewed interest in developing innovative therapeutic options. In particular, novel molecular targeted agents have been shown to have significant anti-tumor activity, and integration of these therapies has led to critical advances in management.

In this volume, an outstanding group of the world's leaders in the field have assembled to convey their knowledge of the epidemiology, biology,...